Riskpilot← Back to searchSign inGet full accessMedilogy Oy
OYDissolvedY-tunnus 3241864-7Iirislahdentie 42-B5Medical specialists activities · NACE 8622Est. 2021— employees
Revenue 2025
EUR 547K
+69% vs 2024
EBITDA margin
70.8%
-10% vs 2024
Equity ratio
14.6%
Financial strength
Net profit 2025
EUR 309K
+63% vs 2024
| Revenue | EUR 547K | +69% |
| EBITDA | EUR 387K | -10% |
| Net profit | EUR 309K | +63% |
| Total assets | EUR 538K | +138% |
| Equity | EUR 79K | -63% |
| Employees | — | — |
Legal name
Medilogy Oy
Y-tunnus number
3241864-7
Legal form
Osakeyhtiö
NACE code
8622 · Medical specialists activities
Founded
13. lokakuuta 2021
Share capital
EUR 0
Employees
—
VAT registered
No
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Toimitusjohtaja yksin
Company purpose
Yhtiön toimiala on lääkäripalvelujen ja muun terveydenhuollon sekä alan suunnittelu-, koulutus- ja konsultointipalvelujen tuottaminen. Terveydenhoitoon liittyvien laitteiden ja välineiden maahantuonti ja kauppa. Maa- ja metsätalous. Asuin-, liike- ja muiden rakennusten uudis- ja korjausrakentaminen sekä rakennuttaminen. Yhtiö voi omistaa, hallita ja vuokrata kiinteistöjä, liike- ja asuinhuoneistoja sekä kulkuneuvoja. Yhtiö voi harjoittaa arvopaperikauppaa. Kaikki muu laillinen liiketoiminta.
Address
Iirislahdentie 42-B5
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | 0 | 53 | 324 | 547 |
| Staff expenses | — | — | 0 | −1 |
| EBITDA | 0 | 68 | 432 | 387 |
| Depreciation & amort. | — | — | 1 | −1 |
| EBIT | 0 | 37 | 236 | 386 |
| Net financials | — | — | — | — |
| Profit before tax | — | 37 | 236 | 386 |
| Tax | −0 | 7 | 47 | −77 |
| Net profit | 0 | 30 | 189 | 309 |
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 0 | 52 | 226 | 538 |
| Equity | 0 | 43 | 215 | 79 |
| Long-term debt | — | — | — | — |
| Short-term debt | 0 | 9 | 11 | 460 |
| Total debt | 0 | 9 | 11 | 460 |
EBITDA margin
70.8%
This company
15.8%
Market median
+348% vs market
20222025
Equity ratio
14.6%
This company
38.2%
Market median
-62% vs market
20222025
Return on equity
392.4%
This company
18.4%
Market median
+2033% vs market
20222025
Net profit margin
56.5%
This company
8.1%
Market median
+598% vs market
20222025
Asset turnover
1.02×
This company
1.12×
Market median
+9% vs market
20222025
Debt / equity
5.84×
This company
0.62×
Market median
-842% vs market
20222025
- Annual report 2025Filed via PRH / YTJ · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via PRH / YTJ · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via PRH / YTJ · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via PRH / YTJ · Period 2021-10-01 – 2022-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
LM Chief Executive Officer | Chief Executive Officer | 2021 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Board of Directors | 2021 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Medilogy Oy also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Lauri Mikael Jouhi | Chief Executive Officer | 0 companies |
| Jenna Susanna Jouhi | Board of Directors | 0 companies |